Abstract
Objective: A deep understanding of the relationship between a scarce drug’s dose and clinical response is necessary to appropriately distribute a supply-constrained drug along these lines.
Summary of key data: The vast majority of drug development and repurposing during the COVID-19 pandemic – an event that has made clear the ever-present scarcity in healthcare systems -has been ignorant of scarcity and dose optimisation’s ability to help address it.
Conclusions: Future pandemic clinical trials systems should obtain dose optimisation data, as these appear necessary to enable appropriate scarce resource allocation according to societal values.
Keywords: CLINICAL PHARMACOLOGY; COVID-19; Clinical trials; MEDICAL ETHICS; Public health; Rationing.
【저자키워드】 COVID-19, public health, clinical trials, clinical pharmacology, medical ethics, rationing, 【초록키워드】 clinical trial, pandemic, COVID-19 pandemic, clinical, resource, dose, rationing, Healthcare system, clinical response, help, Future, Public, majority, 【제목키워드】 resource,